Literature DB >> 15081310

Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase.

Kenneth K Ma1, Tsuneo Ogawa, Adolfo J de Bold.   

Abstract

An increase in circulating brain natriuretic peptide (BNP) but not atrial natriuretic factor (ANF) is observed coincident with cardiac allograft rejection that is reversed upon treatment with anti-lymphocyte therapy suggesting that pro-inflammatory cytokines may uniquely modulate BNP gene expression and secretion. This study tested pro-inflammatory cytokines or conditioned medium (CM) derived from mixed- lymphocyte reaction (MLR) cultures in their ability to modulate ANF or BNP mRNA expression, secretion, as well as BNP promoter activity in cultured neonatal rat cardiocytes. IL-1 beta and TNF-alpha elicited a significant dose- and time-dependent increase in BNP mRNA, and secretion, whereas, ANF mRNA levels and secretion did not change. IL-1 beta and TNF-alpha rapidly increased phosphorylated p38 MAP kinase abundance and activity. Inhibition of p38 MAP kinase with SB203580 abolished IL-1 beta- and TNF-alpha-stimulated increase in BNP mRNA, promoter activity and secretion. MLR-CM in 20%, 50% and 100% proportions increased BNP but not ANF secretion. The MLR-induced increases in BNP secretion were completely abolished by SB203580 pre-treatment. These investigations show that exposure of cultured rat cardiocytes to specific pro-inflammatory cytokines as well as MLR-CM results in the only known instance of upregulation of cardiac BNP at the transcriptional and translational levels without a corresponding increase in ANF gene expression. Furthermore, these effects are dependent on signaling by p38 MAP kinase. In all, the findings reveal a unique dis-coordinated expression of BNP and ANF to inflammatory cytokines and offers an opportunity to better understand the differential regulation of these two cardiac-derived endocrine hormones that share receptors as well as biological properties.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15081310     DOI: 10.1016/j.yjmcc.2004.01.001

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  54 in total

1.  Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial.

Authors:  Sean van Diepen; Matthew T Roe; Renato D Lopes; Amanda Stebbins; Stefan James; L Kristin Newby; David J Moliterno; Franz-Josef Neumann; Justin A Ezekowitz; Kenneth W Mahaffey; Judith S Hochman; Christian W Hamm; Paul W Armstrong; Pierre Theroux; Christopher B Granger
Journal:  J Thromb Thrombolysis       Date:  2012-07       Impact factor: 2.300

Review 2.  Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure.

Authors:  Chaitanya Madamanchi; Hassan Alhosaini; Arihiro Sumida; Marschall S Runge
Journal:  Int J Cardiol       Date:  2014-08-09       Impact factor: 4.164

3.  Elevated N-terminal pro-brain natriuretic peptide in Mycobacterium tuberculosis pulmonary infection without myocardial dysfunction.

Authors:  Simona L Bar; Naser Sayeh; Andrew P Ignaszewski
Journal:  Can J Cardiol       Date:  2009-04       Impact factor: 5.223

4.  NT-proBNP levels may be influenced by inflammation in active ankylosing spondylitis receiving TNF blockers: a pilot study.

Authors:  Julio C B Moraes; Ana C M Ribeiro; Carla G S Saad; Alessandro C Lianza; Clovis A Silva; Eloísa Bonfá
Journal:  Clin Rheumatol       Date:  2013-02-05       Impact factor: 2.980

5.  The Correlation of Serum Brain Natriuretic Peptide and Interleukin-6 with Quality of Life Using the Chronic Obstructive Pulmonary Disease Assessment Test.

Authors:  Hassan Ghobadi; Mohammad Reza Aslani; Adalat Hosseinian; Esmaeil Farzaneh
Journal:  Med Princ Pract       Date:  2017-11-02       Impact factor: 1.927

Review 6.  Assessing cardiovascular risk in children with chronic kidney disease. B-type natriuretic peptide: a potential new marker.

Authors:  Gema Ariceta; Ellen R Brooks; Craig B Langman
Journal:  Pediatr Nephrol       Date:  2005-08-05       Impact factor: 3.714

7.  The relationship among brain natriuretic peptide (BNP), cholesterol and lipoprotein.

Authors:  Hidekazu Takeuchi; Masataka Sata
Journal:  Heart Asia       Date:  2012-01-01

8.  B-type natriuretic peptide and N-terminal pro-BNP in the acute phase of Kawasaki disease.

Authors:  Satoru Iwashima; Takamichi Ishikawa
Journal:  World J Pediatr       Date:  2013-01-18       Impact factor: 2.764

9.  Serum levels of N-terminal pro-B-type natriuretic peptide are associated with allograft function in recipients of renal transplants.

Authors:  Gerd Bodlaj; Rainer Hubmann; Karim Saleh; Georg Biesenbach; Erich Pohanka; Tatjana Stojakovic; Jörg Berg
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

10.  Early Elevated B-Type Natriuretic Peptide Levels are Associated with Cardiac Dysfunction and Poor Clinical Outcome in Pediatric Septic Patients.

Authors:  Jiunn-Ren Wu; I-Chen Chen; Zen-Kong Dai; Jui-Feng Hung; Jong-Hau Hsu
Journal:  Acta Cardiol Sin       Date:  2015-11       Impact factor: 2.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.